Performance Highlights: Q1 FY27 - Dr Lal Pathlabs Ltd

Code BSE: 539524 NSE:

Revenue increased by 19.1% in Q1 FY27 a) EBITDA for Q1 FY27 increased by 28.7% with a margin of 31.0% b) PAT for Q1 FY27 is Rs 170 Cr. with a margin for of 21.4% c) Interim Dividend of 50% i.e. Rs. 5 per share. d) Cash and Cash equivalents as on 30th June 2026 is Rs. 1,693 Cr. e)Acquisition of 80% equity stake in Sunshine Healthcare Limited, Ghana engaged in diagnostic business for a consideration not exceeding GHS 45.6 million.